Cargando…

Adaptive Immunity to Viruses: What Did We Learn from SARS-CoV-2 Infection?

The SARS-CoV-2 virus causes various conditions, from asymptomatic infection to the fatal coronavirus disease 2019 (COVID-19). An intact immune system can overcome SARS-CoV-2 and other viral infections. Defective natural, mainly interferon I- and III-dependent, responses may lead to the spread of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vályi-Nagy, István, Uher, Ferenc, Rákóczi, Éva, Szekanecz, Zoltán
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694482/ https://www.ncbi.nlm.nih.gov/pubmed/36430430 http://dx.doi.org/10.3390/ijms232213951

Ejemplares similares

Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals
por: Szekanecz, Zoltán, et al.
Publicado: (2023)

Pneumococcal vaccination in autoimmune rheumatic diseases
por: Rákóczi, Éva, et al.
Publicado: (2017)

Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy
por: Matula, Zsolt, et al.
Publicado: (2022)

Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans
por: Vályi-Nagy, István, et al.
Publicado: (2021)

Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency
por: Goda, Vera, et al.
Publicado: (2022)

The Effect of Belantamab Mafodotin on Primary Myeloma–Stroma Co-Cultures: Asymmetrical Mitochondrial Transfer between Myeloma Cells and Autologous Bone Marrow Stromal Cells
por: Matula, Zsolt, et al.
Publicado: (2023)

Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine
por: Rákóczi, Éva, et al.
Publicado: (2023)

What else did we learn?
por: Pojer, M
Publicado: (2009)

What did we learn today?
por: Midtvedt, Tore
Publicado: (2015)

Booster Vaccination Decreases 28-Day All-Cause Mortality of the Elderly Hospitalized Due to SARS-CoV-2 Delta Variant
por: Müller, Veronika, et al.
Publicado: (2022)

What did we learn in school today ?
por: Tröster, D A
Publicado: (1989)

Stromal Cells Serve Drug Resistance for Multiple Myeloma via Mitochondrial Transfer: A Study on Primary Myeloma and Stromal Cells
por: Matula, Zsolt, et al.
Publicado: (2021)

What did we know? what did we do?: making decisions in large organizations
por: Herzner, Fred, et al.
Publicado: (2018)

A decennial review of psychotraumatology: what did we learn and where are we going?
por: Olff, Miranda, et al.
Publicado: (2019)

What did we learn with beam in 2008?: Summary of Session 7
por: Lamont, M
Publicado: (2009)

Physiology labs during a pandemic: What did we learn?
por: Chen, Xinnian, et al.
Publicado: (2021)

The national review of asthma deaths: what did we learn and what needs to change?
por: Levy, Mark L.
Publicado: (2015)

LEP/SLC : What did we expect ? What did we achieve ? A very quick historical review
por: Treille, D
Publicado: (2001)

How and what did we do in 1999
por: Despas, C
Publicado: (2000)

Muscle fatigue and muscle weakness: what we know and what we wish we did
por: Karatzaferi, Christina, et al.
Publicado: (2013)

Animal models on HTLV-1 and related viruses: what did we learn?
por: Hajj, Hiba El, et al.
Publicado: (2012)

What did we learn without beam in 2008: Summary of Session 1
por: Saban, R, et al.
Publicado: (2009)

When the dust settles: what did we learn from the bexarotene discussion?
por: Tesseur, Ina, et al.
Publicado: (2013)

Exercise and Mental Health: What did We Learn in the Last 20 Years?
por: Deslandes, Andrea Camaz
Publicado: (2014)

Focus On: The Cardiovascular System: What Did We Learn from the French (Paradox)?
por: Mochly-Rosen, Daria, et al.
Publicado: (2010)

COVID-19 in children: what did we learn from the first wave?
por: Bogiatzopoulou, Aliki, et al.
Publicado: (2020)

The Cause of Severe Acute Respiratory Syndrome: What Did We Learn from It?
por: Peiris, Malik, et al.
Publicado: (2020)

What Did We Learn About Fracture Pain from Animal Models?
por: Radulescu, Andreea, et al.
Publicado: (2022)

COVID19 biomarkers: What did we learn from systematic reviews?
por: Semiz, Sabina
Publicado: (2022)

COVID-19 in congenital heart disease patients: what did we learn?!
por: Zareef, Rana, et al.
Publicado: (2023)

Human milk microbiota: what did we learn in the last 20 years?
por: Selma-Royo, Marta, et al.
Publicado: (2022)

What did we learn (and did not learn) from the pediatric direct oral anticoagulant trials, and how might we better design pediatric anticoagulant trials in the future?
por: Betensky, Marisol, et al.
Publicado: (2023)

Did We Get What We Aimed for 10 Years Ago?
por: Augustinus, A, et al.
Publicado: (2011)

We can do much better than what we did
por: Lee, Sang-Hak
Publicado: (2020)

Sorting the Magnets in the Machine: What did/will We Gain ?
por: Bottura, L
Publicado: (2006)

What did we learn from the extraction experiments with bent crystals at the CERN SPS?
por: Elsener, K, et al.
Publicado: (1998)

LHC Cryogenics: What did we learn from cool-down to first beams
por: Claudet, S
Publicado: (2009)

Five years of the CiPA project (2013–2018): what did we learn?
por: Yim, Dong-Seok
Publicado: (2018)

2 Years into the Pandemic: What Did We Learn About the COVID-19 and Cerebellum?
por: Shaikh, Aasef G., et al.
Publicado: (2022)

SP-0173 ESTRO Education: What did we learn from COVID-19?
por: Eriksen, J.G.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_363f1efke550ccfceqdbmdi4be